What prolonged suspension? Are you suggesting that, despite multiple announcements stating relisting in the near future, the company always knew that it would be over twelve months before it would trade again and therefore mustn’t spend any money?
Have you read the December ‘18 quarterly?
“We are most pleased to advise that our new company is presently finalising a significant and material partnership agreement regarding our medical cannabis formulations and hemp food consumables which will significantly move forward our production schedule and capacity in 2019, focusing on generating substantial short term revenues for our Company. We will be updating the market with further details on this major development in the coming days.”
Not launching aggressive expansion plans? Or the half yearly:
“The Board has been very grateful for the cooperation and assistance provided by the team at Medcan Australia. We are also very excited with the range of new consumable products being released to market from the team at T12, as part of our expanded food range, which was launched on 1st May 2019.”
Not launching aggressive expansion plans?
Or do you really think that management have been working for the last year on the basis that the CR might fail? How disastrous for the company would that have been? But, in any case, it is the job of management to take risks. They have always appeared to be convinced that everything will eventuate, so imo there’s no reason why they shouldn’t have invested the funds for the benefit of the company. And nothing has stopped them borrowing $3.5m through MCL during the last year for investing in the business.
CGB Price at posting:
2.9¢ Sentiment: None Disclosure: Not Held
